OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC

​

OncoC4 has reported positive findings from Phase I/II trials of its investigational bispecific antibody, cesalatamig, as a monotherapy in patients with pre-treated NSCLC.

The post OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.